Mody R, Meyers J, Yu M, Davis K, Levine JA. Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. Curr Med Res Opin. 2022 Nov;38(11):1785-95. doi: 10.1080/03007995.2022.2085962.
Hauber AB, Obi EN, Price MA, Whalley D, Chang CL. Quantifying the relative importance to patients of avoiding symptoms and outcomes of heart failure. Curr Med Res Opin. 2017 Sep;33(11):2027-38. doi: 10.1080/03007995.2017.1355782
Yuan Z, Levitan B, Burton P, Poulos C, Hauber AB, Berlin JA. Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives. Curr Med Res Opin. 2014;30(9):1733-41.
Chopra I, Kamal KM, Candrilli SD. Variations in blood pressure and lipid goal attainment in primary care. Curr Med Res Opin. 2013;29(9):1115-25.
Menzin J, Wygant G, Hauch O, Jackel JL, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin. 2008 Feb;24(2):461-8. doi: 10.1185/030079908X261096 .